Shanghai Caerulum Pharma Discovery

AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor. AZD5153 exhibited excellent pharmacokinetic profile and exhibited high potency in vitro and in vivo effecting c-Myc downregulation and tumor growth inhibition in xenograft studies. AZD5153 showed enhanced potency as a result of bivalent binding and a clear correlation between BRD4 activity and cellular potency.

Shanghai Caerulum Pharma Discovery is the manufacturer of APIs and intermediates of some of the latest compounds in the market. Our focus is on cancer, diabetes and other therapeutic areas.

Shanghai Caerulum Pharma Discovery (CPD) offers high quality and reliable chemical products and integrated biological services including:

1)       Best offer for existing APIs and intermediates

2)       Custom-synthesis APIs and intermediates

3)       DMPK

4)       Biological screening

5)       Drug Safety Evaluation